AU2005245918A1 - Interferon-alpha polypeptides and conjugates - Google Patents

Interferon-alpha polypeptides and conjugates Download PDF

Info

Publication number
AU2005245918A1
AU2005245918A1 AU2005245918A AU2005245918A AU2005245918A1 AU 2005245918 A1 AU2005245918 A1 AU 2005245918A1 AU 2005245918 A AU2005245918 A AU 2005245918A AU 2005245918 A AU2005245918 A AU 2005245918A AU 2005245918 A1 AU2005245918 A1 AU 2005245918A1
Authority
AU
Australia
Prior art keywords
polypeptide
seq
amino acid
sequence
acid positions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2005245918A
Other languages
English (en)
Inventor
Markus Dembowski
Roberto Falkenstein
Stephan Fischer
Adelbert Grossmann
Friederike Hesse
Hans Koll
Harald Kropshofer
Torben Lauesgaard Nissen
Phillip A. Patten
Andreas Schaubmar
Ralf Schumacher
Stefan Seeber
Sridhar Viswanathan
Anne Vogt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Maxygen Inc
Original Assignee
F Hoffmann La Roche AG
Maxygen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG, Maxygen Inc filed Critical F Hoffmann La Roche AG
Publication of AU2005245918A1 publication Critical patent/AU2005245918A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
AU2005245918A 2004-05-19 2005-05-18 Interferon-alpha polypeptides and conjugates Abandoned AU2005245918A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US57250404P 2004-05-19 2004-05-19
US60/572,504 2004-05-19
PCT/US2005/017471 WO2005113592A2 (en) 2004-05-19 2005-05-18 Interferon-alpha polypeptides and conjugates

Publications (1)

Publication Number Publication Date
AU2005245918A1 true AU2005245918A1 (en) 2005-12-01

Family

ID=35428915

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2005245918A Abandoned AU2005245918A1 (en) 2004-05-19 2005-05-18 Interferon-alpha polypeptides and conjugates

Country Status (14)

Country Link
US (9) US7318918B2 (enExample)
EP (1) EP1753779A2 (enExample)
JP (1) JP2008507298A (enExample)
CN (1) CN101115769A (enExample)
AR (1) AR049177A1 (enExample)
AU (1) AU2005245918A1 (enExample)
BR (1) BRPI0511196A (enExample)
CA (1) CA2566247A1 (enExample)
IL (1) IL178470A0 (enExample)
MX (1) MXPA06013412A (enExample)
NO (1) NO20065084L (enExample)
RU (1) RU2006145020A (enExample)
TW (1) TW200611910A (enExample)
WO (1) WO2005113592A2 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000040715A2 (en) * 1999-01-05 2000-07-13 Trustees Of Boston University Improved nucleic acid cloning
US20040005673A1 (en) * 2001-06-29 2004-01-08 Kevin Jarrell System for manipulating nucleic acids
US20030017552A1 (en) * 2000-07-21 2003-01-23 Jarrell Kevin A. Modular vector systems
US7435562B2 (en) 2000-07-21 2008-10-14 Modular Genetics, Inc. Modular vector systems
WO2005112586A2 (en) * 2004-05-12 2005-12-01 Fusionone, Inc. Advanced contact identification system
JP2008519602A (ja) * 2004-11-11 2008-06-12 モジュラー ジェネティクス， インコーポレイテッド 多様性を生じるためのラダーアセンブリおよびシステム
WO2006134497A2 (en) * 2005-03-09 2006-12-21 Guangwen Wei Uses of recombinant super-compound interferons
US7619067B2 (en) * 2005-05-18 2009-11-17 Maxygen, Inc. Evolved interferon-alpha polypeptides
AR078117A1 (es) * 2006-06-20 2011-10-19 Protech Pharma S A Una muteina recombinante del interferon alfa humano glicosilado, un gen que codifica para dicha muteina, un metodo de produccion de dicho gen, un metodo para obtener una celula eucariota productora de dicha muteina, un metodo para producir dicha muteina, un procedimiento para purificar dicha muteina
US20080014616A1 (en) * 2006-07-11 2008-01-17 Kevin Jarrell Methods of introducing targeted diversity into nucleic acid molecules
WO2008013082A1 (en) * 2006-07-25 2008-01-31 Galpharma Co., Ltd. Galectin 9-polymer conjugate
US7808342B2 (en) * 2006-10-02 2010-10-05 Skyworks Solutions, Inc. Harmonic phase tuning filter for RF switches
WO2008124086A2 (en) 2007-04-05 2008-10-16 President And Fellows Of Harvard College Chimeric activators: quantitatively designed protein therapeutics and uses thereof
US7625555B2 (en) 2007-06-18 2009-12-01 Novagen Holding Corporation Recombinant human interferon-like proteins
WO2009006579A1 (en) * 2007-07-05 2009-01-08 Pharmaessentia Corp. Peptide-polymer conjugates
US8106160B2 (en) * 2007-10-01 2012-01-31 Pharmaessentia Corp. N-terminal modified interferon-alpha
US20110034672A1 (en) * 2008-01-18 2011-02-10 Roberto Falkenstein Purification of not-glycosylated polypeptides
US7954022B2 (en) * 2008-01-30 2011-05-31 Alcatel-Lucent Usa Inc. Apparatus and method for controlling dynamic modification of a scan path
RU2563823C2 (ru) * 2008-11-17 2015-09-20 Дженентек, Инк. Способ и композиция для уменьшения агрегации макромолекул при физиологических условиях
EP2391714B2 (en) 2009-01-30 2019-07-24 Whitehead Institute for Biomedical Research Methods for ligation and uses thereof
SG195192A1 (en) * 2011-06-02 2013-12-30 Hanmi Science Co Ltd Non-peptidyl polymer-insulin multimer and method for producing the same
CA2840409A1 (en) 2011-06-28 2013-01-03 Whitehead Institute For Biomedical Research Using sortases to install click chemistry handles for protein ligation
CN102358897B (zh) * 2011-10-31 2013-02-13 北京三元基因工程有限公司 重组人寡腺苷酸合成酶-1的制备方法
WO2015168474A1 (en) 2014-04-30 2015-11-05 President And Fellows Of Harvard College Fusion proteins for treating cancer and related methods
ES2630106T3 (es) * 2014-10-07 2017-08-18 Cyprumed Gmbh Formulaciones farmacéuticas para la administración oral de fármacos peptídicos o proteicos
AU2016380988B2 (en) 2015-12-30 2022-07-21 Genentech, Inc. Formulations with reduced degradation of polysorbate
CN115850521A (zh) * 2016-02-05 2023-03-28 奥里尼斯生物科学私人有限公司 靶向性治疗剂及其用途
RU2650755C1 (ru) * 2017-05-24 2018-04-17 Федеральное государственное бюджетное учреждение "Государственный научный центр "Институт иммунологии" Федерального медико-биологического агентства России (ФГБУ "ГНЦ Институт иммунологии" ФМБА России) Способ очистки лекарственного средства пролонгированного действия на основе рекомбинантного аналога интерферона альфа-17 для лечения вирусного гепатита С
JP2023511946A (ja) * 2020-01-24 2023-03-23 アルカームス ファーマ アイルランド リミテッド 精製方法

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6610830B1 (en) 1980-07-01 2003-08-26 Hoffman-La Roche Inc. Microbial production of mature human leukocyte interferons
ES506955A0 (es) 1980-11-10 1983-02-01 Genentech Inc Un procedimiento para producir un polipeptido antiviral.
US4414150A (en) 1980-11-10 1983-11-08 Genentech, Inc. Hybrid human leukocyte interferons
EP0098876A1 (en) 1982-01-19 1984-01-25 Cetus Corporation Multiclass hybrid interferons
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
JPS60152058A (ja) * 1984-01-20 1985-08-10 Toshiba Corp 半導体記憶装置
ATE78262T1 (de) 1985-06-11 1992-08-15 Ciba Geigy Ag Hybrid-interferone.
US4695626A (en) * 1986-07-29 1987-09-22 Pfizer Inc. 1-aza-4,5-dithiabicyclo [4.2.0] oct-2-en-8-one-2 carboxylate esters
US5372808A (en) 1990-10-17 1994-12-13 Amgen Inc. Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect
JP3496937B2 (ja) 1990-10-17 2004-02-16 アムジエン・インコーポレーテツド コンセンサスヒトインターフェロンを含有する細胞増殖障害治療用の医用組成物
US5595732A (en) 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5382657A (en) 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
US5574138A (en) 1993-03-08 1996-11-12 Immunex Corporation Epithelium-derived T-cell factor
US6335160B1 (en) 1995-02-17 2002-01-01 Maxygen, Inc. Methods and compositions for polypeptide engineering
DK0741577T3 (da) 1994-03-07 2003-02-17 Imperial College Anvendelsen af enterferon, subtype alfa 8, til fremstilling af lægemidler til behandling af virusinfektioner i leveren
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
TW517067B (en) 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
ATE375363T1 (de) 1997-07-14 2007-10-15 Bolder Biotechnology Inc Derivate des wachstumshormons und verwandte proteine
NZ513077A (en) 1999-01-14 2004-03-26 Bolder Biotechnology Inc Methods for making proteins containing free cysteine residues
AU3725600A (en) 1999-03-02 2000-09-21 Maxygen, Inc. Surrogate orphan ligands for orphan receptors
CN1361793A (zh) 1999-05-19 2002-07-31 利思进药品公司 干扰素－α蛋白作为Fc融合蛋白的表达和运输
CA2385045A1 (en) * 1999-10-07 2001-04-12 Maxygen, Inc. Ifn-alpha homologues
US20040002474A1 (en) 1999-10-07 2004-01-01 Maxygen Inc. IFN-alpha homologues
PL356007A1 (en) * 1999-11-12 2004-05-31 Maxygen Holdings Ltd Interferon gamma conjugates
NZ522847A (en) 2000-05-16 2004-11-26 Bolder Biotechnology Inc Methods for refolding proteins containing free cysteine residues
AU2002223350A1 (en) 2000-12-01 2002-06-11 Eleanor N. Fish Cytokine receptor binding peptides
KR100459105B1 (ko) 2001-02-15 2004-12-03 선바이오(주) 변형된 인터페론-알파 2ａ 및 2ｂ, 그리고 이들과 ＰＥＧ유도체와의 배합체
DE60307881T2 (de) 2002-11-15 2007-03-08 F. Hoffmann-La Roche Ag Positionelle isomeren von pegyliertem interferon alpha 2a
AU2003297285A1 (en) 2002-11-18 2004-06-15 Maxygen, Inc. Interferon-alpha polypeptides and conjugates

Also Published As

Publication number Publication date
US20080076710A1 (en) 2008-03-27
WO2005113592A2 (en) 2005-12-01
AR049177A1 (es) 2006-07-05
US20080031853A1 (en) 2008-02-07
US20070020734A1 (en) 2007-01-25
US20070225204A1 (en) 2007-09-27
TW200611910A (en) 2006-04-16
US20070020235A1 (en) 2007-01-25
US7537755B2 (en) 2009-05-26
US7541436B2 (en) 2009-06-02
US20070025966A1 (en) 2007-02-01
NO20065084L (no) 2006-12-01
JP2008507298A (ja) 2008-03-13
US20070225205A1 (en) 2007-09-27
US20080171363A1 (en) 2008-07-17
US7531324B2 (en) 2009-05-12
IL178470A0 (en) 2007-02-11
US7531630B2 (en) 2009-05-12
CA2566247A1 (en) 2005-12-01
US20050266465A1 (en) 2005-12-01
MXPA06013412A (es) 2007-01-23
EP1753779A2 (en) 2007-02-21
US7541163B2 (en) 2009-06-02
CN101115769A (zh) 2008-01-30
BRPI0511196A (pt) 2007-12-04
RU2006145020A (ru) 2008-06-27
US7318918B2 (en) 2008-01-15
WO2005113592A3 (en) 2006-04-06

Similar Documents

Publication Publication Date Title
US7541163B2 (en) Interferon-alpha polypeptides and conjugates
US7314613B2 (en) Interferon-alpha polypeptides and conjugates
US7619067B2 (en) Evolved interferon-alpha polypeptides
AU2003297285A1 (en) Interferon-alpha polypeptides and conjugates
ZA200503782B (en) Interferon-alpha polypeptides and conjugates
KR20070022279A (ko) 인터페론-알파 폴리펩티드 및 컨쥬게이트

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period